These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1122 related articles for article (PubMed ID: 10805117)

  • 1. The role of technetium-99m methoxyisobutylisonitrile scintigraphy in the planning of therapy and follow-up of patients with differentiated thyroid carcinoma after surgery.
    Rubello D; Mazzarotto R; Casara D
    Eur J Nucl Med; 2000 Apr; 27(4):431-40. PubMed ID: 10805117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear medicine approaches in the monitoring of thyroid cancer patients.
    Sergieva S; Hadjieva T; Doldurova M; Stefanova S; Dudov A
    J BUON; 2006; 11(4):511-8. PubMed ID: 17309186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical approach in patients with metastatic differentiated thyroid carcinoma and negative 131I whole body scintigraphy: importance of 99mTc MIBI scan combined with high resolution neck ultrasonography.
    Casara D; Rubello D; Saladini G; Mazzarotto R; Sotti G; Tomasella G; Pelizzo MR
    Tumori; 1999; 85(2):122-7. PubMed ID: 10363078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical importance of technetium-99m-methoxyisobutylisonitrile (MIBI) scintigraphy in differentiated thyroid carcinoma patients with elevated thyroglobulin levels and negative I-131 scanning results.
    Küçük NO; Külak HA; Aras G
    Ann Nucl Med; 2006 Jul; 20(6):393-7. PubMed ID: 16922467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radioiodine whole-body scans, thyroglobulin levels, 99mTc-MIBI scans and computed tomography: results in patients with lung metastases from differentiated thyroid cancer.
    Küçük ON; Gültekin SS; Aras G; Ibiş E
    Nucl Med Commun; 2006 Mar; 27(3):261-6. PubMed ID: 16479246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 99mTc-sestamibi and 131I whole-body scintigraphy and initial serum thyroglobulin in the management of differentiated thyroid carcinoma.
    Ng DC; Sundram FX; Sin AE
    J Nucl Med; 2000 Apr; 41(4):631-5. PubMed ID: 10768563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Diagnostic modalities in patients affected by differentiated thyroid carcinoma with high thyroglobulin levels and total body Iodium-131 negative: PET/CT use after recTSH].
    Biscontini G; Possa M; Sara R; Milella M; Rossetti C
    Minerva Endocrinol; 2004 Dec; 29(4):151-60. PubMed ID: 15765025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Technetium-99m methoxyisobutylisonitrile imaging in the follow-up of differentiated thyroid carcinoma.
    Sriprapaporn J; Toopmongkol C; Satayaban B; Chantamoon N
    Ann Acad Med Singap; 2002 Mar; 31(2):195-8. PubMed ID: 11957557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical utility of technetium-99m methoxisobutylisonitrile imaging in differentiated thyroid carcinoma: comparison with thallium-201 and iodine-131 Na scintigraphy, and serum thyroglobulin quantitation.
    Dadparvar S; Chevres A; Tulchinsky M; Krishna-Badrinath L; Khan AS; Slizofski WJ
    Eur J Nucl Med; 1995 Nov; 22(11):1330-8. PubMed ID: 8575487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Value of
    Okudan B; Seven B; Gülaldı NCM; Çapraz M; Açıkgöz Y
    Curr Med Imaging; 2022; 18(4):404-408. PubMed ID: 34749623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Follow-up of differentiated thyroid cancer: what is the value of FDG and sestamibi in the diagnostic algorithm?
    Dietlein M; Scheidhauer K; Voth E; Theissen P; Schicha H
    Nuklearmedizin; 1998 Jan; 37(1):12-7. PubMed ID: 9467164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thyroglobulin and low-dose iodine-131 and technetium-99m-tetrofosmin whole-body scintigraphy in differentiated thyroid carcinoma.
    Gallowitsch HJ; Mikosch P; Kresnik E; Unterweger O; Gomez I; Lind P
    J Nucl Med; 1998 May; 39(5):870-5. PubMed ID: 9591591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of whole-body 18F-FDG PET, 99mTc-MIBI SPET, and post-therapeutic 131I-Na scintigraphy in the detection of metastatic thyroid cancer.
    Iwata M; Kasagi K; Misaki T; Matsumoto K; Iida Y; Ishimori T; Nakamoto Y; Higashi T; Saga T; Konishi J
    Eur J Nucl Med Mol Imaging; 2004 Apr; 31(4):491-8. PubMed ID: 14666387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neck lymph node metastasis detection in patients with differentiated thyroid carcinoma (DTC) in long-term follow-up: a
    Spanu A; Nuvoli S; Marongiu A; Gelo I; Mele L; Piras B; Madeddu G
    BMC Cancer; 2020 Mar; 20(1):239. PubMed ID: 32197595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic value of technetium-99m methoxyisobutyl isonitrile (99mTc-MIBI) scintigraphy in detecting thyroid cancer metastases: a critical evaluation.
    Alam MS; Kasagi K; Misaki T; Miyamoto S; Iwata M; Iida Y; Konishi J
    Thyroid; 1998 Dec; 8(12):1091-100. PubMed ID: 9920363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of serial serum thyroglobulin determinations after total thyroidectomy for differentiated thyroid cancer.
    Lima N; Cavaliere H; Tomimori E; Knobel M; Medeiros-Neto G
    J Endocrinol Invest; 2002 Feb; 25(2):110-5. PubMed ID: 11929080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical usefulness of 99mTc-MIBI scintigraphy in the postsurgical evaluation of patients with differentiated thyroid cancer.
    Campennì A; Violi MA; Ruggeri RM; Sindoni A; Moleti M; Vermiglio F; Baldari S
    Nucl Med Commun; 2010 Apr; 31(4):274-9. PubMed ID: 20087239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of technetium-99m-MIBI scintigraphy in metastatic differentiated thyroid cancer--comparison study with 131I and 201Tl].
    Nagamachi S; Jinnouchi S; Nishii R; Flores LG; Nakahara H; Futami S; Tamura S; Toshimori H; Kawai K
    Kaku Igaku; 2000 Mar; 37(2):89-98. PubMed ID: 10783567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of 99mTc-methoxyisobutyl isonitrile and 201Tl scintigraphy for detection of residual thyroid cancer after 131I ablative therapy.
    Seabold JE; Gurll N; Schurrer ME; Aktay R; Kirchner PT
    J Nucl Med; 1999 Sep; 40(9):1434-40. PubMed ID: 10492361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of non-specific tracers in the follow up of differentiated thyroid cancer: results with Tc-99m tetrofosmin whole body scintigraphy.
    Lind P; Gallowitsch HJ
    Acta Med Austriaca; 1996; 23(1-2):69-75. PubMed ID: 8767519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.